ZTS — Zoetis Inc.

NYSE · Health Care · Pharmaceuticals · CIK 1555280 ·
Last close
$73.54
Market Cap
$30.39B
52W High
$82.41
52W Low
$70.98
ADV30
6,493,836
Next earnings
2026-11-03
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 2,468,000,000 1,795,000,000 999,000,000 691,000,000 15,077,000,000 1,473,000,000 11,929,000,000
Mar 2026 2,262,000,000 1,621,000,000 822,000,000 601,000,000 15,154,000,000 1,940,000,000 11,921,000,000
Dec 2025 2,387,000,000 1,675,000,000 826,000,000 603,000,000 15,467,000,000 2,310,000,000 12,136,000,000
Sep 2025 2,400,000,000 1,717,000,000 936,000,000 721,000,000 15,159,000,000 2,080,000,000 9,761,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,840,000,000
Investing CF
$-720,000,000
Financing CF
$-2,282,000,000
CapEx
$-524,000,000
Dividends Paid
$-889,000,000
Buybacks
$-3,644,000,000
EPS Diluted TTM
$6.07
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$14,653,000,000
Inventory
$2,574,000,000
Receivables
$1,571,000,000
ST Investments
$200,000,000
EBIT TTM
$3,510,000,000
Pretax Income TTM
$3,272,000,000
Interest Exp TTM
$238,000,000
Analysts
16

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,525,000,192
EBITDA
$4,065,999,872
Free Cash Flow
$2,016,999,936
Enterprise Value
$37,967,462,400
Total Cash
$1,676,000,000
Total Debt
$9,255,000,064
Shares Out
413,223,602
Trailing EPS
$6.13
Book Value
$7.84
ROE
64.9%
ROA
15.4%
Div Yield
2.81%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 9,467,000,000 3,597,000,000 2,673,000,000 15,467,000,000 12,136,000,000 2,904,000,000
Dec 2024 9,256,000,000 3,392,000,000 2,486,000,000 14,237,000,000 9,467,000,000 2,953,000,000
Dec 2023 8,544,000,000 3,069,000,000 2,344,000,000 14,286,000,000 9,295,000,000 2,353,000,000
Dec 2022 8,080,000,000 2,928,000,000 2,114,000,000 14,925,000,000 10,522,000,000 1,912,000,000

TTM Snapshot

Revenues TTM
$8,531,000,000
NetIncome TTM
$2,359,000,000
OpCashFlow TTM
$0
Assets (Latest)
$14,237,000,000
Forward EPS
$6.73

Max Pain — expiry 2026-08-21

max pain strike: $75.00 · spot: $75.84 · call oi: 16,280 · put oi: 17,237
Expected Move to 2026-08-21: ±$3.90 (5.14%) — implied range $71.94$79.74 · ATM straddle on $75.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALNY ALNYLAM PHARMACEUTICALS, INC. $29.97B $223.95
BEIGF BeOne Medicines Ltd. $29.75B $21.95
INSM INSMED Inc $28.89B $132.28
RPRX Royalty Pharma plc $26.37B $59.22
ROIV Roivant Sciences Ltd. $26.12B $36.16

News headlines (Yahoo Finance, 1h cache)

Michael Burry-Backed ZTS Stock Climbs Following FDA Green Light For Dog Pill Against Screwworm
2026-08-13 20:34 · Yahoo
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
2026-08-13 19:51 · Yahoo
Zoetis (ZTS) Q2 2026 Earnings Call Transcript
2026-08-13 12:01 · Yahoo
Michael Burry Adds To NBIS, MU, ORCL Shorts — Says Nebius Is ‘What The Top Of A Boom Looks Like’
2026-08-12 21:33 · Yahoo
Michael Burry Refreshes Bearish Palantir Trade Even As AI Rally Strains Short Bets
2026-08-10 20:01 · Yahoo
Zoetis Stock: Is Wall Street Bullish or Bearish?
2026-08-10 14:44 · Yahoo
Zoetis (ZTS) Looked Like a Winner. What Went Wrong?
2026-08-10 13:09 · Yahoo
US Stock Market Today: S&P 500 Futures Climb On Softer Jobs Data And Yields
2026-08-10 08:11 · Yahoo
ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance
2026-08-10 03:25 · Yahoo
Zoetis Q2 Earnings Call Highlights
2026-08-09 18:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.